John S. Tokarski
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (Sweden)(SE)Bristol-Myers Squibb (Belgium)(BE)
Publications by Year
Research Areas
Cytokine Signaling Pathways and Interactions, HER2/EGFR in Cancer Research, Cancer-related Molecular Pathways, Computational Drug Discovery Methods, Myeloproliferative Neoplasms: Diagnosis and Treatment
Most-Cited Works
- → Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays(2004)1,285 cited
- → The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants(2006)678 cited
- → Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism(1997)414 cited
- → Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165(2019)356 cited
- → Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily(2009)275 cited